文献速递重症综合管理与镇静镇痛心脑血管急症

经鼻高流量空气降低神经重症发热患者核心体温的可行性与安全性:一项先导研究

Feasibility and Safety of Transnasal High Flow Air to Reduce Core Body Temperature in Febrile Neurocritical Care Patients: A Pilot Study.
PubMed 文献 · Neurocrit Care · 2019-01-01
一句话结论经鼻单向高流量空气(20 cmH2O、约57.5 L/min、2小时)可使神经重症监护病房发热患者核心体温从38.4±0.6℃降至37.3±0.5℃,无寒战及方案相关不良事件。

该先导研究纳入7例神经重症监护病房(NCCU)中发热(>37.5℃)持续>24小时且经标准非药物和一线退热药无效的连续患者,经鼻给予医用高流量空气(标准持续气道正压通气机,正压20 cmH2O,持续2小时),连续监测食管和鼓膜核心体温。2小时后核心体温显著低于降温前基线(37.3±0.5℃ vs 38.4±0.6℃,p<0.002),平均经鼻气流率57.5±6.5 L/min,7例中5例在2小时末体温正常;严重高热(39.7℃)1例及因技术原因多次中断治疗1例未降温;停止气流后30分钟内核心体温回升至与降温前基线相似(38.3±0.4℃ vs 38.4±0.6℃,p=NS);核心降温速率为0.6±0.15℃/小时,未观察到寒战反应,无方案相关不良事件。作者认为该先导研究应推动进一步研究。

要点

  • NCCU发热(>37.5℃)持续>24小时且标准非药物和一线退热药无效患者,经鼻高流量空气(20 cmH2O、57.5±6.5 L/min)2小时后核心体温37.3±0.5℃ vs 基线38.4±0.6℃(p<0.002)。
  • 7例中5例在2小时末体温正常;严重高热(39.7℃)1例和因技术原因多次中断治疗1例未降温。
  • 核心降温速率0.6±0.15℃/小时;停止气流后30分钟内核心体温回升至38.3±0.4℃ vs 降温前38.4±0.6℃(p=NS)。
  • 未观察到寒战反应,无方案相关不良事件。
  • 该先导研究应推动进一步研究(作者结论)。

适用人群与场景

  • NCCU中发热(>37.5℃)持续>24小时且经标准非药物和一线退热药无效的连续患者。
  • 研究纳入7例:5例脑出血或脑室内出血,1例横贯性脊髓炎,1例心脏骤停所致缺氧性脑损伤;平均年龄40±14岁,72%(5/7)为男性。

诊断标准与关键阈值

  • 发热定义:体温>37.5℃且持续>24小时。
  • 核心体温监测:连续监测食管和鼓膜温度。

处置流程与药物剂量

  • 经鼻给予医用高流量空气,使用标准持续气道正压通气机,正压20 cmH2O,持续2小时。
  • 平均经鼻气流率57.5±6.5 L/min。
  • 连续监测食管和鼓膜核心体温。

研究设计与关键结果

  • 先导研究,纳入7例NCCU连续发热患者(>37.5℃持续>24小时,标准非药物和一线退热药无效),经鼻高流量空气(20 cmH2O、57.5±6.5 L/min)2小时。
  • 主要结果:2小时后核心体温37.3±0.5℃ vs 降温前基线38.4±0.6℃(p<0.002)。
  • 7例中5例在2小时末体温正常;严重高热(39.7℃)1例和因技术原因多次中断治疗1例未降温。
  • 停止气流后30分钟内核心体温回升至38.3±0.4℃ vs 降温前38.4±0.6℃(p=NS)。
  • 核心降温速率0.6±0.15℃/小时;未观察到寒战反应;无方案相关不良事件。

证据类型、等级与局限

  • 证据类型:先导研究。
  • 局限:原文未报告局限性;作者结论指出该先导研究应推动进一步研究。

对床旁实践的改变

  • 作者认为该先导研究应推动进一步研究;原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Fever is an important determinant of prognosis following acute brain injury. Current non-pharmacologic techniques to reduce fever are limited and induce a shivering response. We investigated the safety and efficacy of a novel transnasal unidirectional high flow air device in reducing core body temperature in the neurocritical care unit (NCCU) setting.

METHODS: This pilot study included seven consecutive patients in the NCCU who were febrile (> 37.5 °C) for > 24 h despite standard non-pharmacologic and first-line antipyretic agents. Medical grade high flow air was delivered transnasally using a standard continuous positive airway pressure machine with a positive pressure of 20 cmH2O for 2 h. Core esophageal and tympanic temperature were continuously monitored.

RESULTS: Mean age was 40 ± 14 yo, and 72% (5/7 patients) were men. Five patients had intracerebral or intraventricular hemorrhage, one subject had transverse myelitis, and the remaining patient had anoxic brain injury due to a cardiac arrest. After 2 h of cooling, core temperature was significantly lower than the baseline pre-cooling temperature (37.3 ± 0.5 °C vs. 38.4 ± 0.6 °C; p < 0.002). Mean transnasal airflow rate was 57.5 ± 6.5 liters per minute. Five of the seven subjects were normothermic at the end of the 2-h period. One subject with severe hyperthermia (39.7 °C) and the other with multiple interruptions to therapy due to technical reasons did not cool. The core temperature within 30 min of cessation of airflow increased and was similar to the pre-cooling baseline temperature (38.3 ± 0.4 °C vs. 38.4 ± 0.6 °C, p = NS). Rate of core cooling was 0.6 ± 0.15 °C per hour at this flow rate. No shivering response was observed. No protocol-related adverse events occurred.

CONCLUSIONS: High flow transnasal air in a unidirectional fashion lowers core body temperature in febrile patients in the NCCU setting. No adverse events were seen, and the process showed no signs of shivering or any other serious side effects during short-term exposure. This pilot study should inform further investigation.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Ziai WC, Shah D, Assis FR, et al. Feasibility and Safety of Transnasal High Flow Air to Reduce Core Body Temperature in Febrile Neurocritical Care Patients: A Pilot Study. Neurocrit Care. 2019. PMID: 30919302. doi:10.1007/s12028-019-00702-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。